Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

ICU

Udo Holtick  1 , Elie Azoulay  2
Nicolaus Kröger  1 , John Gribben  2 , Christian Chabannon  3 , Ibrahim Yakoub-Agha  4 , Hermann Einsele  5
, editors.
In: The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 31.
.
Affiliations
Free Books & Documents
Review

ICU

Udo Holtick et al.
Free Books & Documents

Excerpt

CAR-T cell treatment comes with significant side effects that challenge the structure and capacity of haematology wards and will regularly necessitate intermittent patient transfer to the ICU. Life-threatening adverse events include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, which can occur within hours or days after administration. Sepsis might also require ICU admission within the days that follow CAR-T infusion in these high-risk immunocompromised patients.

PubMed Disclaimer

Sections

References

    1. Azoulay E, Darmon M, Valade S. Acute life-threatening toxicity from CAR-T cell therapy. Intensive Care Med. 2020;46(9):1723–6. https://doi.org/10.1007/s00134-020-06193-1. - DOI - PubMed
    1. Azoulay E, Schellongowski P, Darmon M, et al. The intensive care medicine research agenda on critically ill oncology and hematology patients. Intensive Care Med. 2017;19 https://doi.org/10.1007/s00134-017-4884-z. - DOI - PubMed
    1. Azoulay E, Shimabukuro-Vornhagen A, Darmon M, von Bergwelt-Baildon M. Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be aware and prepared. Am J Respir Crit Care Med. 2019;200(1):20–3. https://doi.org/10.1164/rccm.201810-1945ED. - DOI - PubMed
    1. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124–31. https://doi.org/10.1097/CCM.0000000000002053. - DOI - PMC - PubMed
    1. Gray TF, Temel JS, El-Jawahri A. Illness and prognostic understanding in patients with hematologic malignancies. Blood Rev. 2021;45:100692. https://doi.org/10.1016/j.blre.2020.100692. - DOI - PubMed

LinkOut - more resources